PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
3.56%
Cash & equivalents growing 3.56% while CRVO's declined -86.30%. Peter Lynch would see this as a sign of superior liquidity management.
-100.00%
Both CRVO and the company show zero Short-Term Investments Growth.
3.51%
Below half of CRVO's -86.30%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.27%
Below half of CRVO's -86.93%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
11.32%
Below half CRVO's -17.97%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Non-Current Assets Growth compared to CRVO's zero value, indicating worse performance.
-18.41%
Below half of CRVO's -96.99%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
6.14%
Below half of CRVO's -90.26%. Michael Burry sees a potential red flag for stagnation or capital shortage.
65.90%
Similar yoy growth to CRVO's 76.67%. Walter Schloss sees parallel payables strategy. Check top-line correlation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
126.86%
Less than half of CRVO's -78.03%. David Dodd sees fewer expansions in other current obligations.
114.06%
Less than half of CRVO's -27.69%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
114.06%
Less than half of CRVO's -46.20%. David Dodd sees far fewer liability expansions relative to competitor.
5.13%
Less than half of CRVO's -56.38%. David Dodd sees fewer share issuances vs. competitor.
-6.19%
Below half CRVO's 56.09%. Michael Burry suspects major net losses or high dividends vs. competitor.
-12.13%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to CRVO's zero value, indicating worse performance.
-4.02%
Below half CRVO's -100.22%. Michael Burry sees potential underperformance in building shareholder capital.
6.14%
Below half CRVO's -90.26%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-100.00%
Both CRVO and the company show zero Total Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
-2.49%
Less than half of CRVO's 94.83%. David Dodd sees better deleveraging or stronger cash buildup than competitor.